Weighted Average Number of Shares Outstanding, Diluted of Spyre Therapeutics, Inc. from 31 Dec 2020 to 30 Sep 2024

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Spyre Therapeutics, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 31 Dec 2020 to 30 Sep 2024.
  • Spyre Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 30 Sep 2024 was 50,889,433, a 1085% increase year-over-year.
  • Spyre Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 6,897,065, a 105% increase from 2022.
  • Spyre Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 3,371,231, a 28% increase from 2021.
  • Spyre Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2021 was 2,629,784, a 95% decline from 2020.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

Spyre Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 50,889,433 +46,595,621 +1085% 01 Jul 2024 30 Sep 2024 10-Q/A 18 Nov 2024 2024 Q3
Q2 2024 45,316,264 +41,493,659 +1085% 01 Apr 2024 30 Jun 2024 10-Q/A 18 Nov 2024 2024 Q2
Q1 2024 36,512,662 +32,742,156 +868% 01 Jan 2024 31 Mar 2024 10-Q/A 18 Nov 2024 2024 Q1
Q4 2023 6,897,065 +3,525,834 +105% 01 Oct 2023 31 Dec 2023 10-K/A 18 Nov 2024 2023 FY
Q3 2023 4,293,812 +525,894 +14% 01 Jul 2023 30 Sep 2023 10-Q/A 18 Nov 2024 2024 Q3
Q2 2023 3,822,605 -78,386,427 -95% 01 Apr 2023 30 Jun 2023 10-Q/A 18 Nov 2024 2024 Q2
Q1 2023 3,770,506 -62,225,655 -94% 01 Jan 2023 31 Mar 2023 10-Q/A 18 Nov 2024 2024 Q1
Q4 2022 3,371,231 01 Oct 2022 31 Dec 2022 10-K/A 18 Nov 2024 2023 FY
Q3 2022 3,767,918 -62,021,531 -94% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 82,209,032 +16,577,126 +25% 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2022 65,996,161 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q3 2021 65,789,449 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 65,631,906 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2

Spyre Therapeutics, Inc. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 6,897,065 +3,525,834 +105% 01 Jan 2023 31 Dec 2023 10-K/A 18 Nov 2024 2023 FY
2022 3,371,231 +741,447 +28% 01 Jan 2022 31 Dec 2022 10-K/A 18 Nov 2024 2023 FY
2021 2,629,784 -50,741,946 -95% 01 Jan 2021 31 Dec 2021 10-K/A 18 Nov 2024 2023 FY
2020 53,371,730 01 Jan 2020 31 Dec 2020 10-K 02 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.